Basal-like breast carcinomas: clinical outcome and response to chemotherapy. - Wikidata - wikimedia - TriplyDB

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

http://www.wikidata.org/entity/Q35770209

about

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen Biomarkers in triple negative breast cancer: A review Triple-negative breast cancer: is there a treatment on the horizon?The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.Metaplastic breast carcinomas are basal-like tumours.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients.microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.Treatment options for patients with triple-negative breast cancer Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer MYC and Breast Cancer.Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.The changing role of pathology in breast cancer diagnosis and treatment.Management options in triple-negative breast cancer Significance of rat mammary tumors for human risk assessment.Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer Progression Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.Basal breast cancer: a complex and deadly molecular subtype Demystifying basal-like breast carcinomas Basal-like breast cancer: molecular profiles, clinical features and survival outcomes A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells.Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up International Web-based consultation on priorities for translational breast cancer research.Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.

P2860

Q21092375-37AADF00-9B43-431D-851D-513688D38AA0 Q26775094-3918331B-FD45-4854-ACD3-8D3FFB1D2B1E Q28077243-73630B88-6AC4-4DF9-BE97-8DF86D8F1633 Q30417120-6CE858BE-2988-418C-AD22-A95CD6A64777 Q33250228-8C9B74D7-8BDA-490B-88FC-EE18345412CE Q33291587-22011D22-8D55-4B28-BA28-501A95849B23 Q33506542-E0D905DC-8150-4C0B-8B82-7F18A5347231 Q33576814-BFEB3202-8B24-4EC8-9B8A-B83632C441A3 Q33630849-9876E855-B0BB-4A0B-AAD3-B35AB1F3E914 Q33740256-578A5D63-5895-4D34-9087-7E400562BE03 Q33758934-6E6220EF-329A-47F3-ACA8-DCCEF7DBD75B Q33806378-7FC3221E-4330-487E-94B5-F7CB7003271C Q34088422-947B4EFF-0303-49F3-8B71-A6CF7B1EAA14 Q34331406-0EFC68A7-5ABF-43CA-9C06-32567673708A Q34433737-05CEF46F-61A7-4DCF-AE07-98E4FC7260F0 Q34512811-732D3F5B-30CA-4401-9FA8-D25D4B7ABA0D Q34582473-F9B5E516-D132-4ABF-873C-BA62B2554471 Q34972381-0FC649A2-EDB0-4CCA-BA76-E243D5DC069D Q35010102-BD71A520-93C6-4211-BCF7-C37AF9422E77 Q35042972-61EEA690-FEF2-4B8D-8063-59D6E0C533A7 Q35082260-F6B9A7CF-25A2-406D-B227-21D27EB650C8 Q35155460-35B7FCD4-FA9C-4908-AAA2-A82EF0CD8B64 Q35174533-A0D5C36E-826A-47AA-99A1-140E0A664444 Q35179485-1FDB3AB9-299F-4BF6-8FA3-BB6B163828B8 Q35549438-E3EA2082-9669-458C-8CF6-23F8EF5B0368 Q35558988-6F2EDFF3-BADA-44F3-ABF6-85E7F403E0FA Q35602598-DA083CF4-655E-490C-8F43-CEFAE68F8D39 Q35749393-4D3E10AF-3DA6-4400-BC78-32FCAE2DF63A Q35749421-D7202136-FBAC-4B36-9ECC-0F3A7E3DA565 Q35755182-A10B8D39-6F63-4F4F-B27C-2C6099E85AC0 Q35799667-155CEFA7-BDB5-4734-A20A-A2BAA06355CF Q35909551-910B91C1-411A-4AEB-8399-1B664EFFA60A Q35931900-6E8A285E-7B68-4BE8-BF4F-D93C8429BDC3 Q36172507-F5CCA471-9A60-420F-9EC9-62A5CFAFCD87 Q36325873-69F3DDF3-B0D4-4341-B86E-98FB5099786A Q36369621-AF4B4E42-B1B8-4A9C-B1B7-C1FECD6E0BF7 Q36427883-F5450A1D-7C58-4397-836F-9EA72325747B Q36442340-554F7228-543F-451E-B5F8-5B2D286CF411 Q36465302-B000B731-CAA0-43EE-829C-E7B984C33F9C Q36473913-FA0F80DB-F7E6-4F8D-B895-55515FAED5C4

P2860

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

http://www.wikidata.org/entity/Q35770209

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@ast

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@en

type

label

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@ast

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@en

prefLabel

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@ast

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@en

P1433

Q35770209-FA694610-9F36-4B09-BA3C-432571CA9F19

P1476

Q35770209-E337AB6E-C650-4F24-89B4-6B70EEA34C88

P2093

Q35770209-33E76891-F14E-49D7-A485-BBBDCE12430D

Q35770209-98953D60-1F16-4025-82A0-7AEDA143B8D6

Q35770209-A792D232-6A5B-4ED5-8FE7-D1EE7D2C3686

Q35770209-E7B48762-423C-4A0C-BDF7-5824689512CA

Q35770209-FDE1433B-C15B-45FE-923E-89E65EB6DD6D

P2860

Q35770209-0AF950C3-E668-48C8-B952-C299646C1F2E

Q35770209-0F69A981-DEB8-4A81-99FC-325319F23576

Q35770209-1DAAFFC4-8D24-4B42-9357-637E54881802

Q35770209-23B9220F-AE14-4233-A2A9-26FDEDE276BF

Q35770209-2F8E55F4-B9F3-4B28-9179-75C2E29A4633

Q35770209-313E4900-F3DA-4EF5-A0A5-D49F1A0883BB

Q35770209-3F50C33E-C76F-45F2-8C0B-FDC21DD18998

Q35770209-3F5316E4-0C21-42EC-800E-4A871414D93A

Q35770209-506E5483-9328-45D4-93F9-9E87AF8FC0D4

Q35770209-52C1FFBC-8500-461A-8A8D-C7EC65E566D8

P304

Q35770209-B90FADF7-E6D7-475D-8862-48EC732769A7

P31

Q35770209-6461D714-A878-4743-A707-BC970AFBEFBC

P356

Q35770209-0F725461-68B8-45DF-AE06-DC9FD281DBDE

P407

Q35770209-E69EC179-34B9-430A-9440-1640A5A9F197

P433

Q35770209-A178E089-4403-428C-A995-6492EEF7BF96

P478

Q35770209-F7E616CB-5835-4970-9BA5-9BFCA9218E9F

P50

Q35770209-99EBE482-9F31-414A-A1CD-89123A2744A4

Q35770209-A4AEE037-90C0-4E83-815D-D94757C6630A

P577

Q35770209-18BA7CA7-418B-4B91-A4F4-01D2DC4F2BFE

P5875

Q35770209-58D5D4F1-0D7E-461C-A882-3BA64BC5134C

P698

Q35770209-C7CEE744-1202-4CE3-A7A1-80C883E6F297

P921

Q35770209-7FEEDDAE-62DC-41F9-99CA-E349DE655141

P932

Q35770209-98AE55C3-1331-4D39-B04B-C59E6C48DF12

P356

JCP.2005.033043

P1433

Journal of Clinical Pathology

P1476

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

@en

P2093

Ashley S

http://www.w3.org/2001/XMLSchema#string

Banerjee S

http://www.w3.org/2001/XMLSchema#string

Reis-Filho JS

http://www.w3.org/2001/XMLSchema#string

Smith IE

http://www.w3.org/2001/XMLSchema#string

Steele D

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Repeated observation of breast tumor subtypes in independent gene expression data sets

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Hallmarks of 'BRCAness' in sporadic cancers

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

HER2 as a prognostic factor in breast cancer.

Basal and luminal breast cancers: basic or luminous? (review).

P304

729-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2005.033043

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Sunil R Lakhani

P577

2006-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7222001

http://www.w3.org/2001/XMLSchema#string

P698

16556664

http://www.w3.org/2001/XMLSchema#string

P921

P932

1860434

http://www.w3.org/2001/XMLSchema#string